BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Chavda VP, Gajjar N, Shah N, Dave DJ. Darunavir ethanolate: Repurposing an anti-HIV drug in COVID-19 treatment. European Journal of Medicinal Chemistry Reports 2021;3:100013. [DOI: 10.1016/j.ejmcr.2021.100013] [Cited by in Crossref: 5] [Cited by in F6Publishing: 9] [Article Influence: 5.0] [Reference Citation Analysis]
Number Citing Articles
1 Masaret GS, Farghaly TA, Al-hussain SA, Zaki MEA, Alsaedi AMR, Muhammad ZA. Site-Selectivity of the Reaction of 3-Amino-4-Cyano-5-Phenyl-1 H -Pyrrole-2-Carboxylic Acid Amide with α-Halocarbonyl Compounds. Antimicrobial Activity and Docking Study for COVID-19 of the Products. Polycyclic Aromatic Compounds. [DOI: 10.1080/10406638.2022.2130371] [Reference Citation Analysis]
2 Chavda VP, Yao Q, Vora LK, Apostolopoulos V, Patel CA, Bezbaruah R, Patel AB, Chen Z. Fast-track development of vaccines for SARS-CoV-2: The shots that saved the world. Front Immunol 2022;13:961198. [DOI: 10.3389/fimmu.2022.961198] [Reference Citation Analysis]
3 Chavda VP, Chen Y, Dave J, Chen ZS, Chauhan SC, Yallapu MM, Uversky VN, Bezbaruah R, Patel S, Apostolopoulos V. COVID-19 and vaccination: myths vs science. Expert Rev Vaccines 2022. [PMID: 35980281 DOI: 10.1080/14760584.2022.2114900] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
4 Chavda VP, Patel AB, Vora LK, Apostolopoulos V, Uhal BD. Dendritic cell-based vaccine: the state-of-the-art vaccine platform for COVID-19 management. Expert Rev Vaccines 2022. [PMID: 35929957 DOI: 10.1080/14760584.2022.2110076] [Reference Citation Analysis]
5 Chavda VP, Chhabria MT, Apostolopoulos V. Aged Population and Immunocompromised Patients: Impact on SARS-CoV-2 Variants and Treatment Outcomes. Biologics 2022;2:165-70. [DOI: 10.3390/biologics2030013] [Reference Citation Analysis]
6 Chavda VP, Sonak SS, Munshi NK, Dhamade PN. Pseudoscience and fraudulent products for COVID-19 management. Environ Sci Pollut Res Int 2022. [PMID: 35836045 DOI: 10.1007/s11356-022-21967-4] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
7 Chavda VP, Prajapati R, Lathigara D, Nagar B, Kukadiya J, Redwan EM, Uversky VN, Kher MN, Rajvi P. Therapeutic monoclonal antibodies for COVID-19 management: an update. Expert Opin Biol Ther 2022. [PMID: 35604379 DOI: 10.1080/14712598.2022.2078160] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 7.0] [Reference Citation Analysis]
8 Huang Z, Chavda VP, Vora LK, Gajjar N, Apostolopoulos V, Shah N, Chen Z. 2-Deoxy-D-Glucose and its Derivatives for the COVID-19 Treatment: An Update. Front Pharmacol 2022;13:899633. [DOI: 10.3389/fphar.2022.899633] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 9.0] [Reference Citation Analysis]
9 Chavda VP, Bezbaruah R, Athalye M, Parikh PK, Chhipa AS, Patel S, Apostolopoulos V. Replicating Viral Vector-Based Vaccines for COVID-19: Potential Avenue in Vaccination Arena. Viruses 2022;14:759. [DOI: 10.3390/v14040759] [Cited by in Crossref: 16] [Cited by in F6Publishing: 16] [Article Influence: 16.0] [Reference Citation Analysis]